Search research articles
Contact Us
Filters
Showing results (121-130 of 157) with videos related to
Page
of 16
Sort By:
Psycho-Oncology
|
September 30, 2010
The Meaning-Making intervention (MMi) appears to increase meaning in life in advanced ovarian cancer: a randomized controlled pilot study
Melissa Henry, S Robin Cohen, Virginia Lee, et al.
Menopause (New York, N.Y.)
|
May 14, 2009
Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration
Fernand Labrie, David Archer, Céline Bouchard, et al.
Journal of the National Cancer Institute
|
September 25, 2008
Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers
Andrea Eisen, Jan Lubinski, Jacek Gronwald, et al.
Ticks and Tick-Borne Diseases
|
September 11, 2018
Multi-locus sequence typing of Ixodes ricinus and its symbiont Candidatus Midichloria mitochondrii across Europe reveals evidence of local co-cladogenesis in Scotland
Alaa M Al-Khafaji, Simon R Clegg, Alice C Pinder, et al.
Gynecologic Oncology Reports
|
October 10, 2024
Global distribution and career outcomes of international fellows trained in Canadian gynecologic oncology programs
Omar Touhami, Lara De Guerke, Ly-Ann Teo Fortin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2023
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 20, 2021
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
Christian Marth, Rafal Tarnawski, Alexandra Tyulyandina, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 10, 2024
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)
Ritu Salani, Mary McCormack, Yong-Man Kim, et al.
Nature Communications
|
March 16, 2023
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma
Ainhoa Madariaga, Swati Garg, Nairi Tchrakian, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)
Ritu Salani, Mary McCormack, Yong-Man Kim, et al.
Page
of 16
Search research articles
Search
Showing results (121-130 of 157) with videos related to
Sort By:
Page
of 16
Psycho-Oncology
|
September 30, 2010
The Meaning-Making intervention (MMi) appears to increase meaning in life in advanced ovarian cancer: a randomized controlled pilot study
Melissa Henry, S Robin Cohen, Virginia Lee, et al.
Menopause (New York, N.Y.)
|
May 14, 2009
Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration
Fernand Labrie, David Archer, Céline Bouchard, et al.
Journal of the National Cancer Institute
|
September 25, 2008
Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers
Andrea Eisen, Jan Lubinski, Jacek Gronwald, et al.
Ticks and Tick-Borne Diseases
|
September 11, 2018
Multi-locus sequence typing of Ixodes ricinus and its symbiont Candidatus Midichloria mitochondrii across Europe reveals evidence of local co-cladogenesis in Scotland
Alaa M Al-Khafaji, Simon R Clegg, Alice C Pinder, et al.
Gynecologic Oncology Reports
|
October 10, 2024
Global distribution and career outcomes of international fellows trained in Canadian gynecologic oncology programs
Omar Touhami, Lara De Guerke, Ly-Ann Teo Fortin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2023
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 20, 2021
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
Christian Marth, Rafal Tarnawski, Alexandra Tyulyandina, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 10, 2024
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)
Ritu Salani, Mary McCormack, Yong-Man Kim, et al.
Nature Communications
|
March 16, 2023
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma
Ainhoa Madariaga, Swati Garg, Nairi Tchrakian, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)
Ritu Salani, Mary McCormack, Yong-Man Kim, et al.
Page
of 16